(CLBT) Cellebrite DI - Overview
Sector: Technology | Industry: Software - Infrastructure | Exchange: NASDAQ (USA) | Market Cap: 3.674m USD | Total Return: -2.9% in 12m
Avg Turnover: 23.9M
EPS Trend: 89.9%
Qual. Beats: 1
Rev. Trend: 99.8%
Qual. Beats: 0
Warnings
Overextended 1w
Tailwinds
Idiosyncratic Leader, Tailwind
Cellebrite DI Ltd. (NASDAQ: CLBT) provides a comprehensive suite of digital intelligence software and services designed to manage the full lifecycle of legally sanctioned investigations. Its platform enables government agencies and private corporations to extract, decode, and analyze digital evidence from diverse sources, including mobile devices and cryptocurrency transactions. Key product offerings include the Inseyets forensics software, the Guardian evidence management system, and Pathfinder, an AI-driven analytics tool used to accelerate case resolution across various crime types.
The company operates within the specialized Digital Intelligence (DI) sector, where demand is increasingly driven by the proliferation of encrypted mobile data and the rising volume of digital footprints in criminal activity. Cellebrite utilizes a software-as-a-service (SaaS) and subscription-based business model, providing recurring revenue streams from federal, state, and local law enforcement agencies globally. For a deeper analysis of these metrics, consider reviewing the comprehensive data available on ValueRay.
In addition to core forensics, Cellebrite offers mobile vulnerability research and penetration testing through its Corellium Falcon and Viper tools. The firm also generates revenue through professional services, including technical training and certification for investigators. Headquartered in Israel, the company serves a global market spanning the Americas, EMEA, and Asia-Pacific regions.
- Transition to subscription-based SaaS model accelerates recurring revenue and margin expansion
- Rising digital evidence volumes drive law enforcement demand for AI-powered analytics tools
- Global geopolitical instability increases government spending on counter-terrorism and forensic software
- Expansion into corporate e-discovery and cybersecurity markets diversifies private sector revenue streams
| Net Income: 71.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.13 > 0.02 and ΔFCF/TA 35.75 > 1.0 |
| NWC/Revenue: 37.25% < 20% (prev 56.23%; Δ -18.98% < -1%) |
| CFO/TA 0.18 > 3% & CFO 168.0m > Net Income 71.9m |
| Net Debt (-406.3m) to EBITDA (117.8m): -3.45 < 3 |
| Current Ratio: 1.53 > 1.5 & < 3 |
| Outstanding Shares: last quarter (252.1m) vs 12m ago 1.11% < -2% |
| Gross Margin: 83.86% > 18% (prev 0.84%; Δ 8.30k% > 0.5%) |
| Asset Turnover: 59.73% > 50% (prev 59.05%; Δ 0.69% > 0%) |
| Interest Coverage Ratio: 194.2 > 6 (EBITDA TTM 117.8m / Interest Expense TTM 523k) |
| A: 0.19 (Total Current Assets 535.1m - Total Current Liabilities 350.2m) / Total Assets 952.3m |
| B: -0.08 (Retained Earnings -75.6m / Total Assets 952.3m) |
| C: 0.12 (EBIT TTM 101.6m / Avg Total Assets 831.1m) |
| D: -0.17 (Book Value of Equity -74.6m / Total Liabilities 441.7m) |
| Altman-Z'' = 1.66 = BB |
| DSRI: 0.76 (Receivables 72.7m/81.1m, Revenue 496.4m/419.2m) |
| GMI: 1.00 (GM 83.86% / 84.06%) |
| AQI: 1.78 (AQ_t 0.40 / AQ_t-1 0.22) |
| SGI: 1.18 (Revenue 496.4m / 419.2m) |
| TATA: -0.10 (NI 71.9m - CFO 168.0m) / TA 952.3m) |
| Beneish M = -2.73 (Cap -4..+1) = A |
As of June 02, 2026, the stock is trading at USD 15.87 with a total of 5,233,051 shares traded.
Over the past week, the price has changed by +20.41%,
over one month by +18.88%,
over three months by +17.56% and
over the past year by -2.94%.
Cellebrite DI has received a consensus analysts rating of 4.75. Therefore, it is recommended to buy CLBT.
- StrongBuy: 6
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 21 | 32.3% |
P/E Trailing = 52.6071
P/E Forward = 35.7143
P/S = 7.4014
P/B = 7.2066
Revenue TTM = 496.4m USD
EBIT TTM = 101.6m USD
EBITDA TTM = 117.8m USD
Long Term Debt = 18.2m USD (estimated: total debt 22.8m - short term 4.60m)
Short Term Debt = 4.60m USD (from shortTermDebt, last quarter)
Debt = 22.8m USD (from shortLongTermDebtTotal, last quarter) (leases 22.8m already included)
Net Debt = -406.3m USD (calculated: Debt 22.8m - CCE 429.1m)
Enterprise Value = 3.27b USD (3.67b + Debt 22.8m - CCE 429.1m)
Interest Coverage Ratio = 194.2 (Ebit TTM 101.6m / Interest Expense TTM 523k)
EV/FCF = 26.21x (Enterprise Value 3.27b / FCF TTM 124.7m)
FCF Yield = 3.82% (FCF TTM 124.7m / Enterprise Value 3.27b)
FCF Margin = 25.11% (FCF TTM 124.7m / Revenue TTM 496.4m)
Net Margin = 14.48% (Net Income TTM 71.9m / Revenue TTM 496.4m)
Gross Margin = 83.86% ((Revenue TTM 496.4m - Cost of Revenue TTM 80.1m) / Revenue TTM)
Gross Margin QoQ = 82.53% (prev 84.71%)
Tobins Q-Ratio = 3.43 (Enterprise Value 3.27b / Total Assets 952.3m)
Interest Expense / Debt = 2.29% (Interest Expense 523k / Debt 22.8m)
Taxrate = 19.77% (2.70m / 13.6m)
NOPAT = 81.5m (EBIT 101.6m * (1 - 19.77%))
Current Ratio = 1.48 (Total Current Assets 535.1m / Total Current Liabilities 361.1m)
Debt / Equity = 0.04 (Debt 22.8m / totalStockholderEquity, last quarter 510.5m)
Debt / EBITDA = -3.45 (Net Debt -406.3m / EBITDA 117.8m)
Debt / FCF = -3.26 (Net Debt -406.3m / FCF TTM 124.7m)
Total Stockholder Equity = 462.7m (last 4 quarters mean from totalStockholderEquity)
RoA = 8.65% (Net Income 71.9m / Total Assets 952.3m)
RoE = 13.35% (Net Income TTM 71.9m / Total Stockholder Equity 538.3m)
RoCE = 18.25% (EBIT 101.6m / Capital Employed (Equity 538.3m + L.T.Debt 18.2m))
RoIC = 14.02% (NOPAT 81.5m / Invested Capital 581.2m)
WACC = 7.96% (E(3.67b)/V(3.70b) * Re(8.0%) + D(22.8m)/V(3.70b) * Rd(2.29%) * (1-Tc(0.20)))
Discount Rate = 8.0% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 96.61 | Cagr: 13.37%
[DCF] Terminal Value 75.44% ; FCFF base≈124.7m ; Y1≈125.2m ; Y5≈132.6m
[DCF] Fair Price = 9.90 (EV 2.06b - Net Debt -406.3m = Equity 2.47b / Shares 249.4m; r=8.35% [WACC [floored]]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: 89.89 | EPS CAGR: 39.09% | SUE: 1.48 | # QB: 1
Revenue Correlation: 99.78 | Revenue CAGR: 21.27% | SUE: 0.62 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.11 | Chg30d=-5.21% | Revisions=-11% | Analysts=8
EPS next Quarter (2026-09-30): EPS=0.16 | Chg30d=+0.57% | Revisions=+0% | Analysts=8
EPS current Year (2026-12-31): EPS=0.55 | Chg30d=+2.65% | Revisions=+33% | GrowthEPS=+8.8% | GrowthRev=+19.4%
EPS next Year (2027-12-31): EPS=0.66 | Chg30d=+5.74% | Revisions=+56% | GrowthEPS=+19.2% | GrowthRev=+17.5%
[Analyst] Revisions Ratio: +56%